Literature DB >> 34246724

Association of heart failure subtypes and atrial fibrillation: Data from the Atherosclerosis Risk in Communities (ARIC) study.

Miriam A M Nji1, Scott D Solomon2, Lin Yee Chen3, Amil M Shah2, Elsayed Z Soliman4, Aniqa B Alam1, Vinita Subramanya1, Alvaro Alonso5.   

Abstract

AIMS: To determine the prevalence and incidence of AF among HF subtypes in a biracial community-based cohort.
METHODS: We studied 6496 participants in the Atherosclerosis Risk in Community study (mean age, 75.8 ± 5.3, 59% women, 23% black) who attended the 2011-2013 visit. HF was identified from physician adjudicated diagnosis, hospital discharges, and self-report. HF subtypes were based on echocardiography. A left ventricular ejection fraction <40% represents HF with reduced ejection fraction (HFrEF), 40%-49% for HF with midrange ejection fraction (HFmEF), and ≥ 50% for HF with preserved ejection fraction (HFpEF). AF was ascertained through 2017 from study electrocardiograms, hospital discharges, and death certificates. Confounder-adjusted logistic regression and Cox models were used to estimate associations of HF subtype with prevalent and incident AF.
RESULTS: Among eligible participants, 393 had HF (HFpEF = 232, HFmEF = 41, HFrEF = 35 and unclassified HF = 85) and 735 had AF. Compared to those without HF, all HF subtypes were more likely to have prevalent AF [odds ratio (95% confidence interval (CI)) 7.4 (5.6-9.9) for HFpEF, 8.1 (4.3-15.3) for HFmEF, 10.0 (5.0-20.2) for HFrEF, 8.8 (5.6-14.0) for unclassified HF]. Among participants without AF at baseline (n = 5761), 610 of them developed AF. Prevalent HF was associated with increased risk of AF [hazard ratio (95%CI) 2.3 (1.6-3.2) for HFpEF, 5.0 (2.7-9.3) for HFmEF, 3.5 (1.7-7.6) for HFrEF, 1.9 (0.9-3.7) for unclassified HF].
CONCLUSION: AF and HF frequently co-occur, with small differences by HF subtype, underscoring the importance of understanding the interplay of these two epidemics and evaluating shared preventive and therapeutic strategies.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Epidemiology; Heart failure

Mesh:

Year:  2021        PMID: 34246724      PMCID: PMC8419094          DOI: 10.1016/j.ijcard.2021.07.006

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.039


  31 in total

1.  Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria.

Authors:  Wayne D Rosamond; Patricia P Chang; Chris Baggett; Anna Johnson; Alain G Bertoni; Eyal Shahar; Anita Deswal; Gerardo Heiss; Lloyd E Chambless
Journal:  Circ Heart Fail       Date:  2012-01-23       Impact factor: 8.790

2.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

3.  Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Alvaro Alonso; Faye L Lopez; Kunihiro Matsushita; Laura R Loehr; Sunil K Agarwal; Lin Y Chen; Elsayed Z Soliman; Brad C Astor; Josef Coresh
Journal:  Circulation       Date:  2011-06-06       Impact factor: 29.690

Review 4.  Heart Failure and Atrial Fibrillation, Like Fire and Fury.

Authors:  Matthew A Carlisle; Marat Fudim; Adam D DeVore; Jonathan P Piccini
Journal:  JACC Heart Fail       Date:  2019-06       Impact factor: 12.035

5.  Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population.

Authors:  Susan Colilla; Ann Crow; William Petkun; Daniel E Singer; Teresa Simon; Xianchen Liu
Journal:  Am J Cardiol       Date:  2013-07-04       Impact factor: 2.778

6.  Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.

Authors:  Richard K Cheng; Margueritte Cox; Megan L Neely; Paul A Heidenreich; Deepak L Bhatt; Zubin J Eapen; Adrian F Hernandez; Javed Butler; Clyde W Yancy; Gregg C Fonarow
Journal:  Am Heart J       Date:  2014-07-22       Impact factor: 4.749

7.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

8.  Multiple imputation using chained equations: Issues and guidance for practice.

Authors:  Ian R White; Patrick Royston; Angela M Wood
Journal:  Stat Med       Date:  2010-11-30       Impact factor: 2.373

9.  Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.

Authors:  Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

10.  Relation of Resting Heart Rate to Incident Atrial Fibrillation (From ARIC [Atherosclerosis Risk in Communities] Study).

Authors:  Weijia Wang; Alvaro Alonso; Elsayed Z Soliman; Wesley T O'Neal; Hugh Calkins; Lin Yee Chen; Marie Diener-West; Moyses Szklo
Journal:  Am J Cardiol       Date:  2018-02-21       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.